Anika Therapeutics Inc(ANIK)Finding the best opportunities to buy and sell stocks daily.
Anika Therapeutics, Inc., together with its subsidiaries, operates as an integrated joint preservation, restoration, and regenerative solutions company in the United States, Europe, and internationally. The company's lead products include HYALOMATRIX for the treatment of skin wounds, such as pressure ulcers, diabetic foot ulcers, and deep second-degree burns; and MEROGEL, a woven fleece nasal packing. Its joint pain management products comprise MONOVISC, ORTHOVISC, and CINGAL that are used as hyaluronic acid (HA) based viscosupplements to treat osteoarthritis pain in humans; and HYVISC, a HA-based treatment for equine osteoarthritis pain. In addition, the company offers HYALOFAST, a HYAFF-based support for human bone marrow mesenchymal stem cells used for cartilage regeneration and adjunct for microfracture surgery; and Tactoset, a HA-enhanced bone repair therapy to treat insufficiency fractures. Further, it provides ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; joint surface implant and preservation solutions for knee, shoulder, hip, ankle, wrist, and toe to treat upper and lower orthopedic conditions caused by trauma, injury, and arthritic disease; and surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.